Abivax (AAVXF) Invested Capital (2021 - 2026)

Abivax has reported Invested Capital for 6 years, with the latest figure at $503.4 million in Q1 2026.

• On a quarterly basis, Invested Capital rose 2117.85% year-over-year to $503.4 million in Q1 2026; TTM through Mar 2026 was $503.4 million, a 2117.85% increase from a year earlier, with the FY2025 full-year figure at $530.5 million, up 1023.13% from the prior year.
• Invested Capital was $503.4 million for Q1 2026 at Abivax, down from $530.5 million in the prior quarter.
• The five-year high for Invested Capital was $645.0 million in Q3 2025, with the low at $14.8 million in Q4 2022.
• Average Invested Capital over 5 years is $243.9 million, with a median of $186.6 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Invested Capital tumbled 85.65% in 2025, then jumped 2117.85% in 2026.
• Over 5 years, Invested Capital stood at $14.8 million in 2022, then jumped by 1370.97% to $218.2 million in 2023, then slumped by 78.35% to $47.2 million in 2024, then jumped by 1023.13% to $530.5 million in 2025, then decreased by 5.12% to $503.4 million in 2026.
• The last three Invested Capital figures came in at $503.4 million (Q1 2026), $530.5 million (Q4 2025), and $645.0 million (Q3 2025), per Business Quant data.